ClinicalTrials.gg
RecruitingNCT06839131Updated May 5, 2026

A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.

A Phase 1 interventional study of SPH9788 and Placebo in Healthy Participants, sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety of SPH9788 tablets in healthy subjects.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Shanghai Pharmaceuticals Holding Co., Ltd is the lead sponsor of 35 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects aged from 18 to 45 years;
  2. Subject has a (BMI) between 18.5 and 28.0 kg/m2 at screening and the weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg;;
  3. Subjects who voluntarily participate and sign form;
  4. Subjects who can communicate well with investigator and comply with the lifestyle restrictions specified in the protocol, and cooperate to complete the trial procedure;
  5. Subjects willing to use reliable methods throughout the trial and for 6 months after trial completion.

Exclusion criteria

Exclusion Criteria:

  1. Medical history (current or past) that in the investigator's judgment may interfere with trial participation;
  2. Surgical/medical conditions that may significantly affect drug pharmacokinetics (absorption, distribution, metabolism, excretion) or pose safety risks;
  3. Occurrence of protocol-defined exclusionary events within 3 months prior to product administration;
  4. Use of any prescription/non-prescription medications (including herbal products) within 2 weeks prior to dosing;
  5. Known to any component of the investigational product or history of severe allergic reactions;
  6. Positive serology for surface antigen, antibody, antibody, and syphilis serum reaction;
  7. Substance abuse history within 1 year prior to screening or positive urine drug screen;
  8. Alcohol abuse history within 1 year or positive alcohol breath test;
  9. Smoking ≥5 cigarettes/day on average during 3 months prior to screening;
  10. Pregnant or lactating women;
  11. Positive pregnancy test before study drug administration, or male and female subjects who refuse to use effective methods during and for 6 months post-trial, or who have plans to donate sperm or eggs;
  12. Poor compliance or any other condition that in the investigator's opinion renders the subject unsuitable for trial participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    SPH9788

    Drug: SPH9788

  • Placebo comparator
    Placebo Comparator

    Drug: Placebo

Interventions

  • DrugSPH9788

    SPH9788 tablets administered orally

  • DrugPlacebo

    Matching placebo administered orally

06

What researchers measure

Primary outcomes

  1. (一) Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).

    Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).

    Time frame: Approximately 1 year

Secondary outcomes

  1. PK(Pharmacokinetics):Tmax

    Time to peak plasma concentration (Tmax)

    Time frame: Approximately 1 year

  2. PK(Pharmacokinetics):Cmax

    Maximum serum concentration(Cmax)

    Time frame: Approximately 1 year

  3. PK(Pharmacokinetics):AUC

    Area under the plasma concentration versus time curve (AUC)

    Time frame: Approximately 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 21, 2025
StartActual
Mar 2, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06839131
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Mar 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Huafang Li
Contact
smhcirb@163.com
0086-021-34773308

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion